{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:11:11Z","timestamp":1790266271275,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["PS20-2010"],"award-info":[{"award-number":["PS20-2010"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"DOI":"10.1007\/s10461-026-05304-1","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:51:06Z","timestamp":1790265066000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Barriers and Facilitators to Equitable Implementation of Long-Acting Injectable PrEP for Racial, Gender and Sexual Minority Populations in NYC: The EquiPrEP Study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8955-4303","authenticated-orcid":false,"given":"Ofole","family":"Mgbako","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Kaplan-Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Casey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Goldfarb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandi","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzana","family":"Kapadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahnah","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Felder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Ratcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eishelle H.","family":"Tillery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharen","family":"Duke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo A.","family":"Morales Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Goldberg-Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Pitts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"5304_CR1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"R Landovitz","year":"2021","unstructured":"Landovitz R, Donnell D, Clement M, et al. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021;385:595\u2013608. https:\/\/doi.org\/10.1056\/NEJMoa2101016.","journal-title":"N Engl J Med"},{"issue":"10337","key":"5304_CR2","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa2101016","volume":"7","author":"S Delany-Moretlwe","year":"2022","unstructured":"Delany-Moretlwe S, Hughes J, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet May. 2022;7(10337):1779\u201389. https:\/\/doi.org\/10.1056\/NEJMoa2101016.","journal-title":"Lancet May"},{"key":"5304_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003465","author":"E Cooney","year":"2024","unstructured":"Cooney E, Poteat T, Reisner S, et al. Brief Report: Interest in Long-acting Injectable PrEP Among Transgender Women in Eastern and Southern United States. J Acquir Immune Defic Syndr. 2024. https:\/\/doi.org\/10.1097\/QAI.0000000000003465.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"5304_CR4","doi-asserted-by":"publisher","unstructured":"Kerrigan D, O\u2019Rourke A, Scott R, et al. Social Determinants of Health and Side Effects Significantly Predict Pre-Exposure Prophylaxis (PrEP) Preferences for Every 2 Month Long-Acting Injectable vs. Daily Oral PrEP among Cisgender Women in the United States and the Dominican Republic. Open Forum Infect Dis. 2025;P\u20131415. https:\/\/doi.org\/10.1093\/ofid\/ofae631.1590.","DOI":"10.1093\/ofid\/ofae631.1590"},{"issue":"S2","key":"5304_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26107","volume":"26","author":"L Lorenzetti","year":"2023","unstructured":"Lorenzetti L, Dinh N, Van Der Straten A, et al. Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV acquisition. J Int AIDS Soc. 2023;e26107. https:\/\/doi.org\/10.1002\/jia2.26107.","journal-title":"J Int AIDS Soc"},{"key":"5304_CR6","doi-asserted-by":"publisher","unstructured":"Philbin M, Bergen S, Parish C, et al. Acting Injectable ART and PrEP Among Women in Six Cities Across the United States: A Qualitative Analysis of Who Would Benefit the Most. AIDS Behav. 2022;1260\u20139. https:\/\/doi.org\/10.1007\/s10461-021-03483-7.","DOI":"10.1007\/s10461-021-03483-7"},{"key":"5304_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002577","author":"W Goedel","year":"2020","unstructured":"Goedel W, Bessey S, Lurie M, et al. Projecting the impact of equity-based preexposure prophylaxis implementation on racial disparities in HIV incidence among MSM. AIDS. 2020. https:\/\/doi.org\/10.1097\/QAD.0000000000002577.","journal-title":"AIDS"},{"key":"5304_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26109","author":"S Stansfield","year":"2023","unstructured":"Stansfield S, Heitner J, Mitchell K, et al. Population-level impact of expanding PrEP coverage by offering long-acting injectable PrEP to MSM in three high-resource settings: a model comparison analysis. J Int AIDS Soc. 2023. https:\/\/doi.org\/10.1002\/jia2.26109.","journal-title":"J Int AIDS Soc"},{"key":"5304_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/COH.0000000000000899","volume":"20","author":"R Patel","year":"2025","unstructured":"Patel R, Mayer K. Why is roll-out of long-acting PrEP agents so slow? HIV AIDS. 2025;20:48\u201353. https:\/\/doi.org\/10.1097\/COH.0000000000000899.","journal-title":"HIV AIDS"},{"key":"5304_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.21493","author":"L Mann","year":"2024","unstructured":"Mann L, Zhu W, Huang Y, et al. Trends in oral and injectable HIV preexposure prophylaxis prescriptions in the US, 2013\u20132023. JAMA. 2024. https:\/\/doi.org\/10.1001\/jama.2024.21493.","journal-title":"JAMA"},{"key":"5304_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.1366","author":"J Altamirano","year":"2023","unstructured":"Altamirano J, Shukla P, Barnett S. Early Real-World Experience of Long-Acting Cabotegravir (CAB) for HIV Pre-Exposure Prophylaxis (PrEP) in a Large Community-Based Clinic Network (CAN Community Health): Utilization and PrEP Persistence. Open Forum Infect Dis. 2023. https:\/\/doi.org\/10.1093\/ofid\/ofad500.1366.","journal-title":"Open Forum Infect Dis"},{"key":"5304_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-025-09350-8","author":"D Baker","year":"2025","unstructured":"Baker D, Collins L, Cantos V, et al. Early Implementation of Long-Acting Injectable Cabotegravir for HIV Prevention in a Safety Net Hospital-based Primary Care Center in U.S. South. J Gen Intern Med. 2025. https:\/\/doi.org\/10.1007\/s11606-025-09350-8.","journal-title":"J Gen Intern Med"},{"key":"5304_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003370","author":"S Keddem","year":"2024","unstructured":"Keddem S, Thatipelli S, Caceres O, et al. Barriers and facilitators to long-acting injectable HIV pre-exposure prophylaxis implementation in primary care since its approval in the United States. J Acquir Immune Defic Syndr. 2024. https:\/\/doi.org\/10.1097\/QAI.0000000000003370.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"5304_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000733","author":"M Spinelli","year":"2022","unstructured":"Spinelli M, Grinsztejn B, Landovitz R. Promises and challenges: cabotegravir for preexposure prophylaxis. Curr Opin HIV AIDS. 2022. https:\/\/doi.org\/10.1097\/COH.0000000000000733.","journal-title":"Curr Opin HIV AIDS"},{"key":"5304_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s10508-023-02776-3","author":"F Dillon","year":"2024","unstructured":"Dillon F, Ertl M, Eklund A, et al. Sexual identity development and social ecological facilitators and barriers of PrEP uptake and adherence among Latinx men who have sex with men. Arch Sex Behav. 2024. https:\/\/doi.org\/10.1007\/s10508-023-02776-3.","journal-title":"Arch Sex Behav"},{"key":"5304_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2024.102153","author":"T Washington","year":"2024","unstructured":"Washington T, Applewhite S, Green Y, et al. Recommendations from Black and Latinx sexual minority males to include pharmacists to increase greater accessibility and OnlyFans stars to promote uptake of injectable PrEP. J Am Pharm Assoc. 2024. https:\/\/doi.org\/10.1016\/j.japh.2024.102153.","journal-title":"J Am Pharm Assoc"},{"key":"5304_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000605","author":"M Karris","year":"2020","unstructured":"Karris M, Dube K, Moore A. What lessons it might teach us? Community engagement in HIV research. Curr Opin HIV AIDS. 2020. https:\/\/doi.org\/10.1097\/COH.0000000000000605.","journal-title":"Curr Opin HIV AIDS"},{"key":"5304_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0291657","author":"C Kaul","year":"2023","unstructured":"Kaul C, Moore B, Kapalan-Lewis E, et al. EquiPrEP: An implementation science protocol for promoting equitable access and uptake of long-acting injectable HIV pre-exposure prophylaxis (LAI-PrEP). PLoS ONE. 2023. https:\/\/doi.org\/10.1371\/journal.pone.0291657.","journal-title":"PLoS ONE"},{"key":"5304_CR19","doi-asserted-by":"publisher","DOI":"10.1056\/CAT.22.0371","author":"A Calvo-Friedman","year":"2023","unstructured":"Calvo-Friedman A, Clapp J, Kumar S, et al. Scaling primary care social needs screening and referrals in New York City\u2019s safety-net health system. NEJM Catal. 2023. https:\/\/doi.org\/10.1056\/CAT.22.0371.","journal-title":"NEJM Catal"},{"key":"5304_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-022-01245-0","author":"L Damschroder","year":"2022","unstructured":"Damschroder L, Reardon C, Widerquist MAO, et al. The updated Consolidated Framework for Implementation Research based on user feedback. Implement Sci. 2022. https:\/\/doi.org\/10.1186\/s13012-022-01245-0.","journal-title":"Implement Sci"},{"key":"5304_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002984","author":"D Li","year":"2022","unstructured":"Li D, Benbow N, Keiser B, et al. Determinants of Implementation for HIV Pre-exposure Prophylaxis Based on an Updated Consolidated Framework for Implementation Research: A Systematic Review. J Acquir Immune Defic Syndr. 2022. https:\/\/doi.org\/10.1097\/QAI.0000000000002984.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"5304_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-020-03120-9","author":"J Sales","year":"2021","unstructured":"Sales J, Escoffery C, Hussen S, et al. Pre-exposure prophylaxis implementation in family planning services across the Southern United States: findings from a survey among staff, providers and administrators working in Title X-funded clinics. AIDS Behav. 2021. https:\/\/doi.org\/10.1007\/s10461-020-03120-9.","journal-title":"AIDS Behav"},{"key":"5304_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-020-03152-1","author":"D Turner","year":"2021","unstructured":"Turner D, Lockhart E, Wang W, et al. Examining the factors affecting PrEP implementation within community-based HIV testing sites in Florida: a mixed methods study applying the consolidated framework for implementation research. AIDS Behav. 2021. https:\/\/doi.org\/10.1007\/s10461-020-03152-1.","journal-title":"AIDS Behav"},{"key":"5304_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2020.1810616","author":"C Xavier Hall","year":"2021","unstructured":"Xavier Hall C, Smith J, Driggers R, et al. PrEParing for long-acting injectable PrEP in the South: perspectives from healthcare providers in Georgia. AIDS Care. 2021. https:\/\/doi.org\/10.1080\/09540121.2020.1810616.","journal-title":"AIDS Care"},{"key":"5304_CR25","doi-asserted-by":"publisher","DOI":"10.4135\/9781036232078.n9","volume-title":"Thematic Analysis: A Practical Guide","author":"V Braun","year":"2021","unstructured":"Braun V, Clarke V. Thematic Analysis: A Practical Guide. Sage; 2021."},{"key":"5304_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/0142159X.2022.2057287","author":"F Olmos-Vega","year":"2023","unstructured":"Olmos-Vega F, Stalmeijer R, Varpio L, et al. A practical guide to reflexivity in qualitative research: AMEE guide no. 149. Med Teach. 2023. https:\/\/doi.org\/10.1080\/0142159X.2022.2057287.","journal-title":"Med Teach"},{"key":"5304_CR27","unstructured":"Development AtSS. ATLAS.ti. Software. 2023."},{"key":"5304_CR28","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2023.00867","author":"Y Guo","year":"2024","unstructured":"Guo Y, D\u2019Angelo A, Westmoreland D, et al. PrEP Discontinuation In A US National Cohort Of Sexual And Gender Minority Populations. Health Aff (Millwood). 2024. https:\/\/doi.org\/10.1377\/hlthaff.2023.00867.","journal-title":"Health Aff (Millwood)"},{"issue":"5","key":"5304_CR29","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1093\/cid\/ciae531","volume":"80","author":"M Spinelli","year":"2025","unstructured":"Spinelli M, Bisom-Rapp E, Heise M, et al. High retention and adherence with rapid long-acting injectable preexposure prophylaxis implementation in an urban safety net clinic population. Clin Infect Dis. 2025;80(5):1139\u201342. https:\/\/doi.org\/10.1093\/cid\/ciae531.","journal-title":"Clin Infect Dis"},{"key":"5304_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26095","author":"A Grimsrud","year":"2023","unstructured":"Grimsrud A, Wilkinson L, Delany-Moretlwe S, et al. The importance of the \u2018how\u2019: the case for differentiated service delivery of long-acting and extended delivery regimens for HIV prevention and treatment. J Int AIDS Soc. 2023. https:\/\/doi.org\/10.1002\/jia2.26095.","journal-title":"J Int AIDS Soc"},{"key":"5304_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae648","author":"J Marcus","year":"2025","unstructured":"Marcus J, Weddle A, Kelley C, et al. Policy Recommendations to Support Equitable Access to Long-Acting Injectables for Human Immunodeficiency Virus Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association. Clin Infect Dis Off Pub Infec Dis Soc Am. 2025. https:\/\/doi.org\/10.1093\/cid\/ciae648.","journal-title":"Clin Infect Dis Off Pub Infec Dis Soc Am"},{"key":"5304_CR32","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/COH.0000000000000596","volume":"15","author":"K Meyers","year":"2020","unstructured":"Meyers K, Price D, Golub S. Behavioral and social science research to support accelerated and equitable implementation of long-acting preexposure prophylaxis. Curr Opin HIV AIDS. 2020;15:66\u201372. https:\/\/doi.org\/10.1097\/COH.0000000000000596.","journal-title":"Curr Opin HIV AIDS"},{"key":"5304_CR33","doi-asserted-by":"publisher","DOI":"10.1080\/17441692.2023.2250426","author":"A Smith","year":"2023","unstructured":"Smith A, Lancaster K, Rhodes T, et al. Understanding how PrEP is made successful: Implementation science needs an evidence-making approach. Glob Public Health. 2023https:\/\/doi.org\/10.1080\/17441692.2023.2250426.","journal-title":"Glob Public Health"},{"key":"5304_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26094","author":"M Warren","year":"2023","unstructured":"Warren M, Nyagah W, Hashim C, et al. Shaping and coordinating the implementation science agenda for injectable cabotegravir for PrEP: the role of the Biomedical Prevention Implementation Collaborative (BioPIC). J Int AIDS Soc. 2023. https:\/\/doi.org\/10.1002\/jia2.26094.","journal-title":"J Int AIDS Soc"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-026-05304-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-026-05304-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-026-05304-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:51:09Z","timestamp":1790265069000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-026-05304-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":34,"alternative-id":["5304"],"URL":"https:\/\/doi.org\/10.1007\/s10461-026-05304-1","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"5 September 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"OM and RP have received funding from Viiv Healthcare for an ongoing injectable cabotegravir implementation study.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}